Cardiovascular toxicities associated with novel cellular immune therapies
Abstract: Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cel...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924006141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850108734854922240 |
|---|---|
| author | Malak Munir Ahmed Sayed Daniel Addison Narendranath Epperla |
| author_facet | Malak Munir Ahmed Sayed Daniel Addison Narendranath Epperla |
| author_sort | Malak Munir |
| collection | DOAJ |
| description | Abstract: Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggest that these therapies may be associated with a high incidence of serious cardiovascular toxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these events is a major limitation to long-term survival after these treatments. This review examines the current state of evidence, including reported incidence rates, risk factors, mechanisms, and management strategies of cardiovascular toxicities after treatment with these novel therapies. We specifically focus on CAR-T and BTE therapies and their relation to arrhythmia, heart failure, myocarditis, bleeding, and other major cardiovascular events. Beyond the relationship between cytokine release syndrome and cardiotoxicity, we describe other potential mechanisms and highlight key unanswered questions and future directions of research. |
| format | Article |
| id | doaj-art-4ad338e1530548499095c9767a94dea8 |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-4ad338e1530548499095c9767a94dea82025-08-20T02:38:17ZengElsevierBlood Advances2473-95292024-12-018246282629610.1182/bloodadvances.2024013849Cardiovascular toxicities associated with novel cellular immune therapiesMalak Munir0Ahmed Sayed1Daniel Addison2Narendranath Epperla3Department of Medicine, Ain Shams University Faculty of Medicine, Cairo, EgyptDepartment of Medicine, Ain Shams University Faculty of Medicine, Cairo, Egypt; Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TXDivision of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH; Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OHDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT; Correspondence: Narendranath Epperla, Division of Hematology and Hematologic Malignancies, Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT 84103;Abstract: Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies, have reshaped the treatment of an expanding number of hematologic malignancies, whereas tumor-infiltrating lymphocytes, a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggest that these therapies may be associated with a high incidence of serious cardiovascular toxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these events is a major limitation to long-term survival after these treatments. This review examines the current state of evidence, including reported incidence rates, risk factors, mechanisms, and management strategies of cardiovascular toxicities after treatment with these novel therapies. We specifically focus on CAR-T and BTE therapies and their relation to arrhythmia, heart failure, myocarditis, bleeding, and other major cardiovascular events. Beyond the relationship between cytokine release syndrome and cardiotoxicity, we describe other potential mechanisms and highlight key unanswered questions and future directions of research.http://www.sciencedirect.com/science/article/pii/S2473952924006141 |
| spellingShingle | Malak Munir Ahmed Sayed Daniel Addison Narendranath Epperla Cardiovascular toxicities associated with novel cellular immune therapies Blood Advances |
| title | Cardiovascular toxicities associated with novel cellular immune therapies |
| title_full | Cardiovascular toxicities associated with novel cellular immune therapies |
| title_fullStr | Cardiovascular toxicities associated with novel cellular immune therapies |
| title_full_unstemmed | Cardiovascular toxicities associated with novel cellular immune therapies |
| title_short | Cardiovascular toxicities associated with novel cellular immune therapies |
| title_sort | cardiovascular toxicities associated with novel cellular immune therapies |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924006141 |
| work_keys_str_mv | AT malakmunir cardiovasculartoxicitiesassociatedwithnovelcellularimmunetherapies AT ahmedsayed cardiovasculartoxicitiesassociatedwithnovelcellularimmunetherapies AT danieladdison cardiovasculartoxicitiesassociatedwithnovelcellularimmunetherapies AT narendranathepperla cardiovasculartoxicitiesassociatedwithnovelcellularimmunetherapies |